Company news
Quest Pharmatech Inc. (TSXV:QPT) news
Quest Pharmatech Inc. news releases on 6ix. Latest, Sep 25, 2026: Quest PharmaTech Announces Change of Chief Executive Officer
Press releases & updates
Quest PharmaTech Announces Change of Chief Executive Officer
September 25, 2026
Quest PharmaTech Provides Corporate Update including Voluntary Adoption of CSA Blanket Order 51-93 to File Financial Statements and MD&A on Semi-Annual Basis
May 29, 2026
Quest PharmaTech Announces Results from AGM
August 27, 2025
Quest PharmaTech Announces Opposition to OQPBIOM's Acquisition of AdBioTech
June 10, 2025
Quest PharmaTech Provides Corporate Update
June 2, 2025
Quest PharmaTech Announces Filing of 2024 Year End Financial Statements and Restated Fiscal 2023 Financial Statements, and Appointment of New Director
May 30, 2024
Quest Receives Cash Dividend Payment from OncoQuest
January 30, 2024
Oregovomab Phase III Clinical Study fails futility analysis; Data Safety Monitoring Board Recommends Overall Survival Follow Up for Potential Late Immune Effects and Clinical Benefits
January 23, 2024
Quest PharmaTech Provides Product Development Update
July 10, 2023
Canadian Investment Regulatory Organization Trade Resumption - QPT
June 7, 2023
Quest PharmaTech Clarifies Agreement in Principle with OQP Bio Inc.
June 6, 2023
Canadian Investment Regulatory Organization Trading Halt - QPT
June 6, 2023
Quest PharmaTech Announces Sale of Bioceltran Investment and Return of Photodynamic Therapy Technology License
September 28, 2022
Quest PharmaTech announces two presentations by OncoQuest Pharmaceuticals, Inc. at the 2021 Annual Meeting of the American Association of Clinical Oncologists
June 1, 2021
Quest Provides Update to Immunotherapy Asset Transfer Between OncoQuest Inc. and OncoQuest Pharmaceuticals Inc.
March 26, 2021
Quest Announces that OncoQuest Pharmaceuticals Inc. Doses First Patient in Phase 3 Clinical Trial, FLORA-5, of Company's Lead Investigational Drug, Oregovomab, in Frontline Ovarian Cancer and appoints Dr. Sunil Gupta as Chief Medical Officer
November 9, 2020
Quest Provides Corporate Update
June 4, 2020
IIROC Trading Resumption - QPT
June 2, 2020
Quest Provides Additional Information on OncoQuest Transaction and Announces Delay in Annual Filings
May 29, 2020
UPDATE - IIROC Trading Halt - QPT
May 4, 2020
Quest PharmaTech Announces Results from its April 28, 2020 AGM
May 1, 2020
IIROC Trading Halt - QPT
April 22, 2020
OncoQuest Signs a Definitive Agreement to Sell Drug Portfolio to Dual Industrial for U.S. $300 Million and Commitment to Fund the Oregovomab Phase 3 Clinical Trial in Frontline Ovarian Cancer
April 22, 2020
OncoQuest Announces Publication of Two Reports Related to Oregovomab Phase 2 Clinical Trial, the Company's Lead Investigational Drug in Frontline Ovarian Cancer
March 24, 2020
OncoQuest Announces a U.S.$50 Million Investment by KOSDAQ listed Dual Industrial Co. Ltd.
March 13, 2020
OncoQuest Receives "Notice of Allowance" for Patent Protection of the Administration Schedule of Oregovomab and Chemotherapy for Stage III-IV Ovarian Cancer Patients
September 25, 2019
OncoQuest Lays the Groundwork for Commencement of Phase 3 Study in Frontline Ovarian Cancer
January 25, 2019
Quest PharmaTech Adopts Amendment to By-laws Requiring Advance Notice of Nomination of Directors
December 18, 2018
Quest PharmaTech Announces Adoption of Shareholder Rights Plan
December 3, 2018
Quest PharmaTech Signs License Agreement with OncoCare Therapeutics to Develop and Commercialize Targeted Cancer Therapy Technology in the U.S.
November 28, 2018
Madenco Biosciences Announces Strategic Decision to Drop Consumer Health Products and Focus on Pharmaceutical Product Development
July 20, 2018
Abstract Describing Use of Oregovomab in Pancreatic Cancer to be Published in JCO as Part of ASCO 2018 Meeting
June 1, 2018
Dr. Eliel Bayever Joins OncoQuest as Chief Medical Officer
May 14, 2018
OncoQuest Completes US$6 Million Private Placement
February 6, 2018
Madenco Biosciences Announces Licensing Agreement for Patented EGF Wound Healing Technology
January 3, 2018
Quest PharmaTech Announces Results from its November 2017 AGM
November 6, 2017
OncoQuest Announces Collaboration with TESARO in Recurrent Ovarian Cancer Setting
October 26, 2017
Quest PharmaTech Receives $1,666,667 of Funding Proceeds Through Exercise of Warrants
August 28, 2017
First Patient Enrolled in OncoQuest's Phase 1/2 Study Combining Oregovomab with Hiltonol® in Recurrent Ovarian Cancer
July 26, 2017
Quest PharmaTech Appoints Mr. Mark Lievonen, former President of Sanofi Pasteur Limited, to the Board of Directors
July 19, 2017
OncoQuest Appoints Senior Biotech Investment Banker Hany Awadalla as Senior Vice President and Chief Financial Officer
June 27, 2017
OncoQuest to Present Oregovomab Phase II Interim Clinical Results for Front Line Treatment of Ovarian Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 24, 2017
Madenco Biosciences Creates New Line of Cosmeceuticals to Complement Bellus Skin(TM) Serum for Anti-Aging
May 18, 2017
OncoQuest Announces Enrollment of First Patient in Phase 1/2 Clinical Study Using Combination of Oregovomab with Checkpoint Inhibitor Nivolumab in Recurrent Ovarian Cancer
May 9, 2017
Quest PharmaTech Expands Its Consumer Health Product Pipeline with Clinically Validated Natural Allergy Relief
May 4, 2017
Quest PharmaTech Announces Results from its 2017 AGM
February 15, 2017
OncoQuest Initiates Commercial Scale Oregovomab Manufacturing Program for Treatment of Ovarian Cancer
December 7, 2016
IIROC Trade Resumption - Quest PharmaTech Inc.
November 30, 2016
OncoQuest Announces Positive Interim Results from Its Phase 2b Clinical Study
November 29, 2016
IIROC Trade Halt - Quest PharmaTech Inc.
November 29, 2016